Skip to main content

Living with factor VII deficiency?

NovoSeven® RT has the proven effectiveness you expect from your treatment.

Controls bleeds, wherever they happen.

NovoSeven® RT is proven effective to treat FVIId at home and is 93% effective at stopping nonsurgical and surgical bleeds in people with FVIId.a  


a
From an analysis of published cases and people who took part in trials and registries.

Chart: NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) was 93% effective at stopping nonsurgical and surgical bleeds in patients with congenital factor VII deficiency

Effectively control bleeds.

90% efficacy in bleed control in trial patients.


Young boy kneeling at a table

Portability that fits an active lifestyle.

NovoSeven® RT is room temperature stable up to 77°F, so you can be on the go.b And, with compact packaging, you can take it along where you need to go.

bNovoSeven® RT should be stored between 36°F and 77°F.
For complete storage information, please see Prescribing Information.


Quick to mix.c

NovoSeven® RT with MixPro® makes mixing a dose as easy as attach, twist, and mix. The prefilled syringe saves time—there are no extra steps to fill a syringe with diluent.

After mixing, NovoSeven® RT may be stored at room temperature in the vial for up to 3 hours.

cCompared with mixing using histidine vials.


Fast to infuse.

NovoSeven® RT provides low infusion volume, so infusing takes 2 to 5 minutes.d NovoSeven® RT is given as an intravenous (IV) bolus injection.

 

dAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.

Pie Chart: NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) takes 2 to 5 minutes to infuse

Established safety profile that comes from experience.e

NovoSeven® RT is a recombinant product, meaning it is made without human blood or plasma, which minimizes the possibility of viral contamination. Plus a low rate of blood clots has been reported in clinical trials.

 

eCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

What if I need surgery or a procedure?

We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT prevents bleeds during and after surgery and procedures in people with FVIId.

Talk to your doctor for more information on the surgical use of NovoSeven® RT.

What about surgery and procedures?

Approved for surgical use and procedures for patients with FVIId.

Hear a patient's story.

Meet Taylor. NovoSeven® RT fits in with what she likes to do.

Young man and boy standing

Hear from people who

share your experience.


Illustration: Removing syringe cap

New to treatment? It's

easy to get started.


Icon: 5-step purification process of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Recombinant manufacturing

minimizes risk of viral contamination.


Selected Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven® RT?

  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
    • congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
    • history of heart or blood vessel diseases
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information